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a  b  s  t  r  a  c  t
Lymphoma  should  be  considered  early  in  patients  with  HIV  when  there  is  a history  of  weight  loss.
Although  B-cell  lymphoma  is an  AIDS-deﬁning  cancer,  and many  reports  of lymphoma  in  HIV positive
patients  exist  in the  literature,  this  case  report  illustrates  that  even  in  patients  with  well-controlled  HIV
the  diagnosis  must  be considered,  and  puts  forward  an  unusual  presentation  in an  otherwise  asymp-
tomatic  patient.
A  52  year old  woman  presented  for a  routine  HIV  follow-up  appointment  and  was  found  to  be experi-
encing  weight  loss.  An  abdominal  examination  revealed  a right  iliac  fossa  mass.  Subsequent  CT thorax,
abdomen,  pelvis  imaging  conﬁrmed  a large  mass  but  did not  allow  determination  of  the  primary  source.
Serological  tumour  marker  investigations  were  unyielding.  Trans-vaginal  ultrasound  guided  biopsy  ofiagnostics the mass  demonstrated  diffuse  large  B-cell  lymphoma.
This  case  report  emphasises  the  importance  of  having  a high  index  of  suspicion  for these  cancers  even
in  patients  with  low  viral  load  who  are  on anti-retroviral  treatment.  It  also  demonstrates  the importance
of  taking  a  multidisciplinary  approach  to  diagnosis  of the  condition  to  enable  prompt  treatment  and  thus
improve  the outcome  for the  patient.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Diffuse large B cell lymphoma is known to arise in the general
opulation, as well as in patients who are HIV positive. However,
ome types of lymphoma, such as plasmablastic lymphoma of the
ral cavity, are much more speciﬁc to HIV positive patients. Lym-
homa can arise in a wide variety of anatomical locations and cases
f GI lymphoma in HIV positive patients are well documented [1].
The incidence of lymphoma in HIV positive patients has
ecreased in recent years, which is presumed to be due to more
ffective anti-retroviral therapy. Also, the type of lymphoma seen is
hanging with non-cleaved lymphoma becoming less common and
iffuse large B-cell lymphoma becoming more common. However,
espite the effectiveness of modern anti-retroviral therapy, there
oes not seem to be a great change in the survival of patients with
IV who are diagnosed with lymphoma [2]. This case illustrates
he need for the diagnosis to be considered early on in patients
ith HIV, even those who are on HAART and who present with
ell-controlled HIV.
∗ Corresponding author. Present address: Eastbourne District General Hospital,
ing’s Drive, East Sussex, United Kingdom.
E-mail address: pkm.foster@doctors.org.uk (P. Foster).
ttp://dx.doi.org/10.1016/j.ijscr.2016.02.032
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Presentation of case
A 52 year-old lady attended a HIV regular review appointment
and was  found to have experienced signiﬁcant weight loss. The
patient had lost 12 kg (20% of her original body weight) over the
last year. At ﬁrst, this had been gradual and the patient stated
that it was intentional. However, over recent months it appeared
to have accelerated. The patient had no other symptoms and was
feeling well. Speciﬁcally, there was no change in bowel habit, no
blood in her stool and no gynaecological symptoms. There was  no
history of fevers or night sweats. The patient had well-controlled
HIV (viral load <40 and count CD4 290). Abdominal examination
revealed a palpable mass in the right iliac fossa (RIF). Biochemical
investigation demonstrated that the haemoglobin concentration
had dropped from 13 g/dL to 10 g/dL and that lactate dehydroge-
nase (643 U/L) and CRP (80 mg/L) were raised. The white cell count
was normal.
The past medical history included a hysterectomy for micro-
invasive carcinoma of the cervix in 2002. However this was carried
out at a different hospital and no notes were available. Following
the ﬁnding of a RIF mass, an urgent CT thorax, abdomen and pelvis
was requested which showed a 15 cm mass (Fig. 1) possibly arising
from the vaginal wall and which may  have had a communication
with the caecum via a ﬁstula. Mesenteric nodes were seen measur-
ing up to 27 mm,  however there was  no evidence of metastases
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. A CT scan showing a pelvic mass. Arrow points to approximate midpoint of
the  mass, which at this point was  14 cm at the widest diameter.
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tig. 2. The histiological results of a transvaginal ultrasound guided punch biopsy.
a)  tru-cut biopsies of lymphoid tissue. (b) High magniﬁcation right showing small
o  intermediate sized lymphoid blasts with numerous mitotic ﬁgures (arrows).
n the liver, lung or bone. From the CT alone it was  difﬁcult to
etermine the origin of the mass. Biochemical serum proﬁling of
he tumour was also unyielding (CA19-9, CAE and CA 125 were all
egative).
A transvaginal ultra-sound guided punch biopsy was taken
Fig. 2) and histological analysis plus immunohistochemistry was
erformed. Tumour cells were >90% positive for Ki67 (a nuclear
roliferation marker) and were conﬁrmed to be CD20 positive B-
ells of germinal center phenotype (Bcl6, Bcl10 + ve). The cells were
egative for the Pan T-cell markers CD3, CD5 and Cyclin D1. This
llowed a diagnosis of high-grade B-cell lymphoma.
The patient was treated with ‘R-CHOP’ therapy: Rituximab,
yclophosphamide, doxorubicin, vincristine and prednisolone,
very 21 days for 6–8 cycles. At the time of writing this report the
atient was undergoing treatment.
. Discussion
Lymphoma is more common in people with HIV compared with
he general population [3] and it is the second most common can-
er in HIV positive patients (second to Kaposi’s sarcoma). It is an
IDs-deﬁning illness regardless of the CD4 count and viral load. The
ubtype of lymphoma in this patient was found to be diffuse large
-Cell lymphoma, which has been shown to be the most common
ype of lymphoma in HIV positive patients [4]. There are a num-PEN  ACCESS
gery Case Reports 21 (2016) 115–117
ber of proposed reasons for the increased incidence of lymphoma
in HIV positive patients such as hyper-activation of lymphocyte
turnover and decreased immunity to viruses such as Epstein–Barr
virus [5]. However, HIV is not the only risk factor for developing
lymphoma and a number of other exposures are also thought to
increase the likelihood diffuse large B-cell lymphoma including
Helicobacter pylori,  hepatitis C and some pesticides [6].
A recent study from South Africa showed that large B cell lym-
phoma presents at a signiﬁcantly younger age in those with HIV.
The study also contributed to evidence that the survival of those
with HIV and lymphoma is much worse than those with lymphoma
who do not have HIV [7].
For a patient presenting from the general population with a
raised CRP and a right iliac fossa mass there are a number of pri-
mary differentials. These include gynaecological, gastrointestinal
and urological causes. One could also categorise differentials into
malignant, benign and infectious. Much further down the list of dif-
ferentials is lymphoma. However with the background of weight
loss and HIV this differential should have been higher on the list.
A CT scan allowed us to identify the size and location of the
mass and rule out major metastases. However, the scan did not
allow determination of the primary source of the mass. Serological
tumour marker assessment inconclusive. However, lactate dehy-
drogenase was  elevated and CRP was  also elevated which is a
picture consistent with lymphoma. It has been shown that an
increased lactate dehydrogenase at presentation of lymphoma is
a poor prognostic sign. Eventually it was a biopsy plus immunohis-
tochemistry that eventually provided a deﬁnitive diagnosis.
Weight loss is a ‘red ﬂag’ symptom for malignancy and lym-
phoma is common in people with HIV. It is therefore imperative
that lymphoma should be considered early in people with lym-
phoma. In practice the general medical knowledge that lymphoma
is increased in HIV positive patients is not widespread. Clinicians
making the link sooner will potentially help many patients, espe-
cially where the patient is HIV positive. Furthermore, if a patient
is found to have lymphoma, a HIV test could be considered. Whilst
CT imaging provided an indication of the position and potential
for spread of the mass, biopsy and immunohistochemistry even-
tually allowed a diagnosis of diffuse large B-cell lymphoma and
commencement of appropriate therapy. This demonstrated the
importance of taking a multidisciplinary approach to diagnosis of
these tumours, which when organised effectively can dramatically
speed up the process of diagnosis. There have been advances in the
ﬁeld of immunohistochemistry recently, which make diagnosis of
lymphoma subtype more speciﬁc [8,9].
Gastrointestinal occurrence of lymphoma is not uncommon in
the HIV-positive population. A Canadian study showed that over a
12-year period, in a population of 1086HIV-positive patients, there
were 39 cases of lymphoma and 13 of these were of the GI tract.
The study showed that abdominal pain and weight loss were the
two most common symptoms [10]. Nakazuru et al. [11] reported
an unusual case of a HIV-associated duodenal lymphoma, which
presented with melena. Gynaecological occurrences of lymphoma
in HIV positive patients are less common although there is a case
report of a HIV-associated lymphoma of the ovary [12]. The origin
of the lymphoma in this case was unclear, although gastrointestinal
seems the most likely.
4. Conclusion
A diagnosis of diffuse B-cell lymphoma in a HIV positive patient
should not be missed. Early diagnosis in such cases can potentially
lead to better treatment and improved outcome. Patients with HIV
and concurrent lymphoma have poor quality of life and survival.
Despite recent advances in anti-retroviral therapy and increases in
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ife expectancy in people with HIV, the survival of patients who
re diagnosed with lymphoma while being HIV positive is still very
oor. Clinicians should be more aware of the increased incidence
f lymphoma in the HIV positive patients to allow quicker diag-
osis. In this case, a number of investigative tests were required
nd a variety of medical specialities involved before gaining a diag-
osis. The ﬁnal diagnosis of large B-cell lymphoma was  eventually
onﬁrmed with a biopsy and immunohistochemistry.
Learning points:
 This case illustrates the need for lymphoma to be suspected
in any HIV positive patient presenting with suspicious symp-
toms, regardless of viral load or CD4 count, emphasising that
AIDS-deﬁning malignancy can occur even in patients with well-
controlled HIV.
 These conditions can be present even in patients who appear oth-
erwise systemically well and in whom routine blood tests may  be
deranged, emphasising the need to involve speciﬁc investigations
early on.
 It also demonstrates the importance of a multidisciplinary
approach to diagnosis in order to expedite the commencement of
treatment and achieve the best possible outcome for the patient.
. Methods
This work has been reported in line with the CARE criteria [13].
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